title: [Current aspects of D-penicillamine and pregnancy].
abstract: Although the outcome of most pregnancies is normal under D-penicillamine a teratogenic effect of the drug is known from animal studies. A few cases of children with birth defects whose mothers received D-penicillamine during pregnancy are reported in the literature. Whether D-penicillamine therapy should be performed throughout pregnancy or whether it should be interrupted depends on the disease to be treated. While in patients with morbus Wilson, continuous treatment with D-penicillamine is justified, it is advisable to interrupt the therapy during pregnancy in patients with rheumatoid arthritis.
authors.affiliation: Klinik Wendelstein der BfA, Bad Aibling.
authors.forename: W
authors.initials: W
authors.lastname: Miehle
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003555:Cystinuria / Q000188:drug therapy*; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D010396:Penicillamine
vernacular_title: Aktuelles zu D-Penicillamin und Schwangerschaft.